Current disease status-Recurrent lymphoma Page 2 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent lymphoma Posts on Medivizor

Searching for patients to try a new therapy for non-responsive lymphoma after stem-cell transplant.

Posted by on Mar 15, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma...

Read More

Searching for patients with relapsed or unresponsive classical HL to try this new treatment option

Posted by on Mar 15, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This Phase 3 trial is evaluating the effectiveness of brentuximab vedotin (Adcetris) with or without nivolumab (Opdivo) for patients with relapsed or unresponsive classical Hodgkin’s lymphoma (cHL). The main outcome to be measured will be survival outcomes at 4 years after treatment. The details Treatment remains...

Read More

Long-term outcomes of radioimmunotherapy for patients with follicular lymphoma

Posted by on Jan 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of radioimmunotherapy (RIT) in patients with follicular lymphoma (FL). This study concluded that RIT is a safe and effective long-term treatment option for these patients. Some background FL is the most common type of non-Hodgkin’s lymphoma. The current standard first-line treatment for...

Read More

Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma

Posted by on Jan 17, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...

Read More

Evaluating second-line rituximab-bendamustine treatment for patients with follicular lymphoma

Posted by on Jan 12, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the BR (bendamustine, rituximab) regimen as a second-line treatment for patients with follicular lymphoma (FL) who had disease progression (tumor growth or spread) after chemoimmunotherapy. The study concluded that this regimen was effective in these patients. Some background...

Read More

Evaluating a new targeted therapy with or without itacitinib for relapsed or refractory lymphoma

Posted by on Dec 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of a new targeted therapy (INCB040093) with or without itacitinib in patients with relapsed or refractory (does not respond to treatment) lymphoma. This study concluded that this new agent was well-tolerated and showed promising effectiveness in these patients.  Some background...

Read More

Evaluating brentuximab vedotin plus gemcitabine in children and young adults with relapsed or refractory Hodgkin’s lymphoma

Posted by on Dec 5, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) plus gemcitabine (Gemzar) in children and young adults with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that this combination is safe and shows promising effectiveness in these...

Read More

Searching for patients with relapsed or refractory Hodgkin’s lymphoma to try pembrolizumab plus GVD

Posted by on Dec 3, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This trial is evaluating the effects of second-line pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, doxorubicin) for relapsed (recurrent cancer) or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). The main outcome to be measured is the number of patients who achieve a complete response...

Read More

Evaluating resminostat for patients with relapsed or refractory Hodgkin’s lymphoma

Posted by on Nov 30, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of resminostat in heavily pre-treated patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that resminostat was effective and well-tolerated in these patients. Some background Histone deacetylase inhibitors (HDIs)...

Read More

Evaluating survival outcomes after brentuximab vedotin treatment for relapsed or refractory Hodgkin’s lymphoma

Posted by on Nov 22, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the impact of brentuximab vedotin (Adcetris) on the survival of patients with relapsed or refractory (does not respond to treatment) classical Hodgkin’s lymphoma (cHL). This study concluded that brentuximab vedotin significantly improved survival in these patients. Some background Patients with cHL who...

Read More

Evaluating the long-term outcomes of brentuximab vedotin after stem cell transplantation for classical Hodgkin’s lymphoma

Posted by on Oct 29, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term survival and safety of brentuximab vedotin (Adcetris) treatment for patients with classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation (auto-SCT; patient's own healthy stem cells are retrieved and then returned into the body after cancer has been removed with chemotherapy...

Read More

Evaluating the impact of older age on patient outcomes after allogenic stem cell transplantation for NHL

Posted by on Oct 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the impact of older age on the outcomes of patients with non-Hodgkin’s lymphoma (NHL) who underwent allogeneic stem cell transplantation (alloSCT). This study concluded that alloSCT in patients older than 65 was associated with higher risks. Some background More than 60% of patients with NHL are older than...

Read More